← All trials

NCT05254912

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date
Mar 7, 2022
Primary completion
Apr 22, 2022
Completion date
Apr 22, 2022
First posted
Feb 24, 2022
Last posted
Aug 26, 2022
Enrollment
50
Arms / groups
3 / —
Source
AACT · ctgov ingestion

Sponsors

  • DSMLead sponsor
  • DSMStudy director
  • EurofinsOverall official - principal investigator

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.